# Lot No. 1

- **Source:** TED · `375509-2025`
- **Buyer:** Amgros I/S
- **Published:** 2025-06-11
- **Deadline:** —
- **Estimated value:** 11,765,767 EUR
- **CPV codes:** 33600000
- **NUTS codes:** DK011, DNK
- **Notice type:** can-standard / 29

## Description

ATC Code: J01DH02, Generic Name: Meropenem, Pharmaceutical form: Injection and Infusion Fluid, Strength: 500 mg, Pack size: Vial, Unit: 3 g, Quantity in units: Denmark: 5.578, Iceland: 433, Norway: 2.000. ATC Code: J01DH02, Generic Name: Meropenem, Pharmaceutical form: Injection and Infusion Fluid, Strength: 1000 mg, Pack size: Vial, Unit: 3 g, Quantity in units: Denmark: 176.842, Iceland: 11.000, Norway: 60.000. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

## Award result

- **Total awarded:** 11,800,000 EUR
- **Contract concluded:** 2024-09-30
- **Winner:** EQL Pharma AB (CVR 556564-9661), Navamedic AB (CVR 556713-3425), FrostPharma AB (CVR 556814-1708) · value 11,800,000 EUR · 3 bids received

## Original notice

https://ted.europa.eu/da/notice/-/detail/375509-2025